AstraZeneca's potential $400B deal with Bristol Myers Squibb puts pharma strategists under scrutiny. No layoffs have been announced, but overlapping functions are obvious merger targets—and AI can already support drug funding decisions. The open question is who gets to decide which medicines survive when strategy teams are consolidated. Protected or redundant? Pick a side in the comments.
